BRL-201

N/A

Report date: 2024/11/14 17:34:31

Base Information

Drug NameBRL-201
Drug Alias Name靶向CD19非病毒PD1定点整合CAR-T（上海邦耀生物）BRL-201PD1-19bbzPD1-19bbz CAR-T
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, B-CellLymphoma, Non-HodgkinLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBRL Medicine Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBRL Medicine IncBeijing T&L Biotechnology Co LtdPorton Pharma Solutions Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, B-CellLymphoma, Non-Hodgkin
Inactive IndicationsLeukemia

Other Information

ATC CodeN/A
Related LinksN/A